Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate PSA response rates of the combination of
Doxil and Thalidomide in patients with AIPC who have failed chemotherapy. Secondary
objectives include: 1) To evaluate the clinical response rate of this combination on
measurable disease 2) To evaluate overall survival for this combination.